Gregory Renza
Stock Analyst at RBC Capital
(3.69)
# 872
Out of 4,412 analysts
146
Total ratings
38.17%
Success rate
10%
Average return
Main Sectors:
28 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintains: Outperform | $22 → $23 | $12.36 | +86.08% | 7 | Apr 11, 2024 | |
| ALPN Alpine Immune Sciences | Downgrades: Sector Perform | $41 → $65 | $64.56 | +0.68% | 4 | Apr 11, 2024 | |
| AMGN Amgen | Reiterates: Outperform | $329 | $269.98 | +21.86% | 10 | Apr 3, 2024 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $70 | $20.40 | +243.14% | 1 | Mar 28, 2024 | |
| FUSN Fusion Pharmaceuticals | Reiterates: Sector Perform | $21 | $21.42 | -1.96% | 4 | Mar 21, 2024 | |
| LIFE aTyr Pharma | Maintains: Outperform | $19 → $16 | $1.57 | +919.11% | 5 | Mar 15, 2024 | |
| VSTM Verastem | Reiterates: Outperform | $32 | $9.38 | +241.15% | 5 | Mar 15, 2024 | |
| ADCT ADC Therapeutics | Reiterates: Outperform | $8 | $4.34 | +84.33% | 10 | Mar 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Sector Perform | $9 → $2 | $0.70 | +185.71% | 9 | Mar 14, 2024 | |
| FULC Fulcrum Therapeutics | Initiates: Outperform | $14 | $7.14 | +96.08% | 1 | Mar 13, 2024 | |
| CRMD CorMedix | Maintains: Outperform | $10 → $9 | $5.31 | +69.49% | 3 | Mar 13, 2024 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $35 → $30 | $16.71 | +79.53% | 11 | Mar 12, 2024 | |
| INO Inovio Pharmaceuticals | Reiterates: Sector Perform | $11 | $10.57 | +4.07% | 6 | Mar 7, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $53 → $45 | $26.33 | +70.91% | 6 | Mar 1, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Outperform | $195 | $109.46 | +78.15% | 7 | Feb 29, 2024 | |
| XNCR Xencor | Reiterates: Outperform | $32 | $19.98 | +60.16% | 5 | Feb 28, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Outperform | $43 → $53 | $39.94 | +32.70% | 8 | Feb 21, 2024 | |
| AGIO Agios Pharmaceuticals | Maintains: Outperform | $43 → $42 | $31.49 | +33.38% | 1 | Feb 16, 2024 | |
| EXEL Exelixis | Maintains: Outperform | $26 → $28 | $23.70 | +18.14% | 3 | Feb 7, 2024 | |
| VRDN Viridian Therapeutics | Reiterates: Outperform | $35 | $12.88 | +171.74% | 6 | Dec 14, 2023 | |
| VIRX Viracta Therapeutics | Maintains: Outperform | $7 → $6 | $0.83 | +624.38% | 6 | Nov 10, 2023 | |
| APTO Aptose Biosciences | Maintains: Outperform | $23 → $18 | $1.22 | +1,375.41% | 7 | Nov 10, 2023 | |
| VRCA Verrica Pharmaceuticals | Maintains: Outperform | $11 → $14 | $6.87 | +103.78% | 4 | Jul 25, 2023 | |
| AVTX Avalo Therapeutics | Downgrades: Sector Perform | $2,160 → $180 | $15.94 | +1,029.23% | 4 | Jun 27, 2023 | |
| NUVB Nuvation Bio | Maintains: Outperform | $6 → $5 | $2.68 | +86.57% | 3 | May 5, 2023 | |
| MORF Morphic Holding | Maintains: Outperform | $75 → $80 | $28.07 | +185.00% | 5 | Apr 26, 2023 | |
| APRE Aprea Therapeutics | Maintains: Sector Perform | $100 → $80 | $5.20 | +1,438.46% | 4 | Mar 16, 2022 | |
| ITRM Iterum Therapeutics | Maintains: Outperform | n/a | $1.67 | - | 1 | Dec 11, 2019 |
Nurix Therapeutics
Apr 11, 2024
Maintains: Outperform
Price Target: $22 → $23
Current: $12.36
Upside: +86.08%
Alpine Immune Sciences
Apr 11, 2024
Downgrades: Sector Perform
Price Target: $41 → $65
Current: $64.56
Upside: +0.68%
Amgen
Apr 3, 2024
Reiterates: Outperform
Price Target: $329
Current: $269.98
Upside: +21.86%
Jasper Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $70
Current: $20.40
Upside: +243.14%
Fusion Pharmaceuticals
Mar 21, 2024
Reiterates: Sector Perform
Price Target: $21
Current: $21.42
Upside: -1.96%
aTyr Pharma
Mar 15, 2024
Maintains: Outperform
Price Target: $19 → $16
Current: $1.57
Upside: +919.11%
Verastem
Mar 15, 2024
Reiterates: Outperform
Price Target: $32
Current: $9.38
Upside: +241.15%
ADC Therapeutics
Mar 14, 2024
Reiterates: Outperform
Price Target: $8
Current: $4.34
Upside: +84.33%
Spruce Biosciences
Mar 14, 2024
Downgrades: Sector Perform
Price Target: $9 → $2
Current: $0.70
Upside: +185.71%
Fulcrum Therapeutics
Mar 13, 2024
Initiates: Outperform
Price Target: $14
Current: $7.14
Upside: +96.08%
CorMedix
Mar 13, 2024
Maintains: Outperform
Price Target: $10 → $9
Current: $5.31
Upside: +69.49%
ACADIA Pharmaceuticals
Mar 12, 2024
Maintains: Outperform
Price Target: $35 → $30
Current: $16.71
Upside: +79.53%
Inovio Pharmaceuticals
Mar 7, 2024
Reiterates: Sector Perform
Price Target: $11
Current: $10.57
Upside: +4.07%
Pacira BioSciences
Mar 1, 2024
Maintains: Outperform
Price Target: $53 → $45
Current: $26.33
Upside: +70.91%
Jazz Pharmaceuticals
Feb 29, 2024
Reiterates: Outperform
Price Target: $195
Current: $109.46
Upside: +78.15%
Xencor
Feb 28, 2024
Reiterates: Outperform
Price Target: $32
Current: $19.98
Upside: +60.16%
IDEAYA Biosciences
Feb 21, 2024
Maintains: Outperform
Price Target: $43 → $53
Current: $39.94
Upside: +32.70%
Agios Pharmaceuticals
Feb 16, 2024
Maintains: Outperform
Price Target: $43 → $42
Current: $31.49
Upside: +33.38%
Exelixis
Feb 7, 2024
Maintains: Outperform
Price Target: $26 → $28
Current: $23.70
Upside: +18.14%
Viridian Therapeutics
Dec 14, 2023
Reiterates: Outperform
Price Target: $35
Current: $12.88
Upside: +171.74%
Viracta Therapeutics
Nov 10, 2023
Maintains: Outperform
Price Target: $7 → $6
Current: $0.83
Upside: +624.38%
Aptose Biosciences
Nov 10, 2023
Maintains: Outperform
Price Target: $23 → $18
Current: $1.22
Upside: +1,375.41%
Verrica Pharmaceuticals
Jul 25, 2023
Maintains: Outperform
Price Target: $11 → $14
Current: $6.87
Upside: +103.78%
Avalo Therapeutics
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $15.94
Upside: +1,029.23%
Nuvation Bio
May 5, 2023
Maintains: Outperform
Price Target: $6 → $5
Current: $2.68
Upside: +86.57%
Morphic Holding
Apr 26, 2023
Maintains: Outperform
Price Target: $75 → $80
Current: $28.07
Upside: +185.00%
Aprea Therapeutics
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $5.20
Upside: +1,438.46%
Iterum Therapeutics
Dec 11, 2019
Maintains: Outperform
Price Target: n/a
Current: $1.67
Upside: -